Oncological resection, myasthenia gravis and staging as prognostic factors in thymic tumours: a Chilean case series

Salas, Patricio; Eliana Solovera, Maria; Bannura, Felipe; Munoz-Medel, Matias; Cordova-Delgado, Miguel; Sanchez, Cesar; Ibanez, Carolina; Garrido, Marcelo; Koch, Erica; Acevedo, Francisco; Mondaca, Sebastian; Nervi, Bruno; Madrid, Jorge; Pena, Jose; Pinto, Mauricio P.; et. al.

Abstract

Background: Thymic epithelial tumours are rare and highly heterogeneous. Reports from the United States suggest an overall incidence of 0.15 per 100,000/year. In contrast, the incidence of these tumours in Latin America is largely unknown and reports are scarce, somewhat limited to case reports. Methods: Herein, we report a series of 38 thymic tumours from a single institution, retrospectively incorporated into this study. Patient characteristics and outcomes including age, sex, stage, paraneoplastic syndromes, treatment regimens and the date of decease were obtained from medical records. Results: Most cases in our series were females and young age (50 years old) and early stage by Masaoka-Koga or the Moran staging systems. Also, a 34% of patients had myasthenia gravis (MG). Next, we analysed overall survival rates in our series and found that the quality of surgery (R0, R1 or R2), MG status and staging (Masaoka-Koga, Moran or TNM) were prognostic factors. Finally, we compared our data to larger thymic tumour series. Conclusions: Overall, our study confirms complete surgical resection as the standard, most effective treatment for thymic epithelial tumours. Also, the Masaoka-Koga staging system remains as a reliable prognostic factor but also the Moran staging system should be considered for thymomas.

Más información

Título según WOS: Oncological resection, myasthenia gravis and staging as prognostic factors in thymic tumours: a Chilean case series
Título de la Revista: ECANCERMEDICALSCIENCE
Volumen: 15
Editorial: CANCER INTELLIGENCE LTD
Fecha de publicación: 2021
DOI:

10.3332/ecancer.2021.1201

Notas: ISI